Evidence map›Paper›PMID 40689785›Full record

ReviewAntimicrobial agents and chemotherapy2025

New Perspectives on Antimicrobial Agents: Pivmecillinam.

Brandon K Hawkins, Helen Ding, Melphine M Harriott, James L Wang

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07407673 (Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07407673 phase3not yet recruitingnot on this mapstarted 2027, after this paper: background citation

Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study

TypeinterventionalSponsorSusanne Dam Nielsen, MD, DMScRan2027 to 2041Enrolled180ConditionsKidney Transplant Infection, Bloodstream Infection, Kidney Transplant, Kidney Transplant RecipientsArmsPivmecillinam, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brandon K HawkinsDepartment of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, Tennessee, USA.ORCID 0000-0001-7735-1130
Helen DingDepartment of Pharmacy, University of Tennessee Medical Center, Knoxville, Tennessee, USA.ORCID 0009-0002-9372-4210
Melphine M HarriottHealthcare-Associated Infections and Antimicrobial Resistance Program of the Communicable and Environmental Diseases and Emergency Preparedness Division, Tennessee Department of Health, Nashville, Tennessee, USA.
James L WangDivision of Infectious Diseases, University of Tennessee Medical Center, Knoxville, Tennessee, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pivmecillinam is a prodrug of mecillinam, a semi-synthetic penicillin, that has recently been U.S. Food and Drug Administration approved for the treatment of uncomplicated urinary tract infections (UTIs) in the United States. Mecillinam demonstrates activity against a variety of common uropathogens, including Enterobacterales such as

Indexed as

Amdinocillin PivoxilAnti-Bacterial AgentsUrinary Tract Infectionsbeta-LactamasesEnterobacteriaceaeEscherichia coliHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsAmdinocillin PivoxilAnti-Bacterial Agentsbeta-Lactamasesamdinocillinclinical dataEnterobacteralesextended-spectrum beta-lactamase producerspivmecillinamreviewurinary tract infections

Identifiers

PMID40689785
PMCPMC12326968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.